Theseus Pharmaceuticals Inc THRX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 08/12/22 EDT
8.00UNCH (UNCH)
Volume
987
Close
8.00quote price arrow up+0.20 (+2.56%)
Volume
17,082
52 week range
4.86 - 24.54
Loading...
  • Open7.97
  • Day High8.10
  • Day Low7.85
  • Prev Close7.80
  • 52 Week High24.54
  • 52 Week High Date10/07/21
  • 52 Week Low4.86
  • 52 Week Low Date06/14/22

Key Stats

  • Market Cap309.60M
  • Shares Out38.70M
  • 10 Day Average Volume0.04M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-36.91

KEY STATS

  • Open7.97
  • Day High8.10
  • Day Low7.85
  • Prev Close7.80
  • 52 Week High24.54
  • 52 Week High Date10/07/21
  • 52 Week Low4.86
  • 52 Week Low Date06/14/22
  • Market Cap309.60M
  • Shares Out38.70M
  • 10 Day Average Volume0.04M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-36.91

RATIOS/PROFITABILITY

  • EPS (TTM)-0.86
  • P/E (TTM)-9.29
  • Fwd P/E (NTM)-5.38
  • EBITDA (TTM)-33.424M
  • ROE (TTM)-
  • Revenue (TTM)0.00
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date11/17/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Theseus Pharmaceuticals Inc

There is no recent news for this security.

Profile

MORE
Theseus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on treating cancer patients through the discovery, development and commercialization of targeted therapies. Its development programs are designed to address drug resistance mutations in oncogenes, which are mutated genes that cause cancer. The Company is focused on developing tyrosine kinase inhibitors (TKI), which is rooted in the critical role that tyrosine kinases play in the development...
Iain Dukes Ph.D.
Executive Chairman of the Board, Co-Founder
Timothy Clackson Ph.D.
President, Chief Executive Officer, Director
Bradford Dahms
Chief Financial Officer
Address
314 Main Street, Suite 04-200
Cambridge, MA
02142
United States